Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International : CDK 4/6 dosing study supports DiviTumŪTKa as an early and effective tool in treatment monitoring and prediction of response

11/19/2020 | 02:01am EST

Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, will be presented at the world´s leading breast cancer conference, SABCS. The study supports using DiviTum®TKa to monitor efficacy during treatment and predict response to the CDK 4/6 inhibitor palbociclib.

“The results from our study support using DiviTum®TKa to monitor efficacy during treatment and predict response to palbociclib, a standard therapy for women with metastatic breast cancer. It is interesting to learn that DiviTum®TKa can identify progression many months ahead of imaging,” said Jairam Krishnamurthy, Lead Author of the study at Division of Oncology/Hematology, University of Nebraska Medical Center.

The current study examines the capability of DiviTum®TKa to be an early predictor of treatment efficacy, and also as a tool for serial monitoring of women with metastatic breast cancer. The study tests a new dosing schedule of a CDK 4/6 inhibitor (palbociclib) and uses DiviTum®TKa to predict response of the therapy. Serum samples were collected pre-treatment and during therapy from 51 patients.

Results show that patients with a tumor response or no disease progression as their best response had significantly lower DiviTum®TKa values at baseline than patients with progressive disease as their best response. During serial monitoring a rise in thymidine kinase activity (TKa) was a predictor of disease progression more than three months prior to imaging progression. The study investigators conclude that serum TKa levels at baseline and on-therapy dynamics show promise for response prediction and monitoring of palbociclib therapy.

“One of our original hypotheses with the DiviTum®TKa test was that TKa levels would be a strong predictor of the treatment effect of cell cycle regulating therapies. In examining the relationship between TKa and treatment with a CDK 4/6 inhibitor, we see strong clinical data that supports that hypothesis. We are very appreciative of the work done by the investigators and their patients to further advance the science.” said Anders Rylander, CEO of Biovica.

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
01/18BIOVICA INTERNATIONAL : DiviTumŪTKa in early treatment resistance trial
AQ
01/16BIOVICA INTERNATIONAL : FDA resource reallocation continues to impact DiviTumŪTK..
AQ
01/12BIOVICA INTERNATIONAL : CEO and main shareholder lends shares for redemption of ..
AQ
2020BIOVICA INTERNATIONAL : Q2 Interim Report August-October 2020/2021
AQ
2020BIOVICA INTERNATIONAL : DiviTumŪTKa included in new UK breast cancer study
AQ
2020BIOVICA INTERNATIONAL : Multicenter study PYTHIA presents positive DiviTumŪTKa r..
AQ
2020BIOVICA INTERNATIONAL : CDK 4/6 dosing study supports DiviTumŪTKa as an early an..
AQ
2020BIOVICA INTERNATIONAL : announces initial results in clinical genomics study of ..
AQ
2020BIOVICA INTERNATIONAL : DiviTumŪTKa Monitoring Capabilities Confirmed in SWOG St..
AQ
2020BIOVICA INTERNATIONAL : FDA submission will proceed to substantive review
AQ
More news
Financials
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,60 M -4,60 M
Net cash 2021 134 M 15,9 M 15,9 M
P/E ratio 2021 -29,6x
Yield 2021 -
Capitalization 1 168 M 140 M 139 M
EV / Sales 2021 345x
EV / Sales 2022 24,2x
Nbr of Employees 21
Free-Float 75,2%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Technical analysis trends BIOVICA INTERNATIONAL AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 67,00 SEK
Last Close Price 41,30 SEK
Spread / Highest target 149%
Spread / Average Target 62,2%
Spread / Lowest Target -24,9%
EPS Revisions
Managers and Directors
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors